Christie + Co
Essential reading for the healthcare business
 
 
Remember me:
Skip Navigation Links
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.
 

Posted on: 26/09/2011

Latest news stories

28/07/2016
London and New York-based investor Octopus Ventures has led a £9.2 million funding round into digital health company Big Health.
27/07/2016
UK real estate investment trust Primary Health Properties has announced improvements in net rental income, but a fall in profits for the half-year ended 30 June 2016.
26/07/2016
Private healthcare provider and insurer Bupa has appointed Evelyn Bourke as chief executive.
26/07/2016
AIM-listed public sector software provider Idox has acquired health and social care software firm Open Objects for £5.2 million.
25/07/2016
NHS England and NHS Improvement have produced a seven point-action plan to tackle the health service’s deficit.




Recent months have seen US REITs become a little quieter in the UK healthcare sector due to problems both here and at home. Luke Cloherty investigates
Read more...


Christie + Co



Healthcare at Home has had its troubles in the past. Ploy Radford talks to its CEO and private equity investor about how the company has rebuilt its reputation and moved on
Read more...


Candesic’s Floris Wentholt, Dr Joe Taylor and Marc Kitten explore the market for CPAP in obstructive sleep apnoea
Recent months have seen US REITs become a little quieter in the UK healthcare sector due to problems both here and at home. Luke Cloherty investigates
Clare Connell and Charlotte Bushnell of Connell Consulting investigate the potential of a new treatment for Alzheimer’s disease
The world of healthcare finance is a broad and ever expanding beast with varied options available for those looking to raise capital. Here, HealthInvestor looks at the world of asset financing
Social housing providers help those most in need, especially in austere times. Can they also provide investors looking for safer, more socially conscious investments with an opportunity, asks Luke Cloherty

Click here to search all feature articles












Search news
and features



Go




Opera